Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
07:30am, Tuesday, 03'rd Sep 2024
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx Announces Participation in September Investor Events
07:30am, Tuesday, 27'th Aug 2024
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
09:50am, Thursday, 08'th Aug 2024
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21.
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
07:30am, Thursday, 08'th Aug 2024
JENA, Germany, Aug. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
07:30am, Thursday, 01'st Aug 2024
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today
InflaRx Hosts R&D Event Highlighting the Promise of INF904
12:00pm, Wednesday, 05'th Jun 2024
JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a v
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data pr
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
07:30am, Wednesday, 08'th May 2024
JENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced f
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
07:30am, Wednesday, 24'th Apr 2024
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced tha
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
09:46am, Thursday, 21'st Mar 2024
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
07:00am, Thursday, 21'st Mar 2024
JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
07:30am, Tuesday, 19'th Mar 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Appoints Jan Medina as Head of Investor Relations
07:30am, Thursday, 22'nd Feb 2024
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
07:30am, Thursday, 25'th Jan 2024
ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by
